Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Miltenyi Biomedicine GmbH
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07569965CT.gov Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL | — | Not Yet Recruiting | — | — | — |
NCT07444710CT.gov Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07341191CT.gov Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | — | Recruiting | — | — | — |
NCT07261163CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT07225439CT.gov Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | — | Not Yet Recruiting | — | — | — |
NCT07259070CT.gov Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT07029737CT.gov A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain | — | Recruiting | — | — | — |
NCT06859008CT.gov Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT07024147CT.gov JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06839053CT.gov Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | — | Recruiting | — | — | — |
Show 138 more trialsShow fewer
NCT06854003CT.gov BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06846489CT.gov Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06742996CT.gov A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | — | Recruiting | — | — | — |
NCT06564038CT.gov A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | — | Recruiting | — | — | — |
NCT06697184CT.gov A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | — | Recruiting | — | — | — |
NCT06208735CT.gov CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | — | Recruiting | — | — | — |
NCT06054776CT.gov Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06656221CT.gov A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06343376CT.gov Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | — | Terminated | — | — | — |
NCT07168486CT.gov CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | — | Enrolling By Invitation | — | — | — |
NCT06504199CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06029309CT.gov Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06253663CT.gov Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT06191887CT.gov B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05951959CT.gov A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05004064CT.gov Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06136351CT.gov A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06026319CT.gov CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05665530CT.gov A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | — | Completed | — | — | — |
NCT05432635CT.gov Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05665062CT.gov Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT05694364CT.gov Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | — | Completed | — | — | — |
NCT05564052CT.gov A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT05934097CT.gov FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05495464CT.gov A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05155215CT.gov Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
NCT04626791CT.gov Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT04855695CT.gov Avo In R/R And Previously Untreated MCL | — | Recruiting | — | — | — |
NCT04765111CT.gov Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04792489CT.gov DALY II USA/ MB-CART2019.1 for DLBCL | — | Recruiting | — | — | — |
NCT04880434CT.gov Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | — | Completed | — | — | — |
NCT05097443CT.gov Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04662255CT.gov Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | — | Active Not Recruiting | — | — | — |
NCT04783415CT.gov Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04735471CT.gov A Phase 1 Study of ADI-001 in B Cell Malignancies | — | Terminated | — | — | — |
NCT04844086CT.gov RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | — | Terminated | — | — | — |
NCT04767308CT.gov Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | — | Unknown | — | — | — |
NCT05164770CT.gov Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT04566887CT.gov Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04736914CT.gov Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT04195633CT.gov Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | — | Recruiting | — | — | — |
NCT04484012CT.gov Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT04223765CT.gov Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | — | Recruiting | — | — | — |
NCT04545762CT.gov Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT04402138CT.gov Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT04189757CT.gov Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03617484CT.gov Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT03579888CT.gov CD19-Specific T Cells Post AlloSCT | — | Terminated | — | — | — |
NCT04282018CT.gov Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | — | Completed | — | — | — |
NCT03932331CT.gov Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT04323657CT.gov TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT03842696CT.gov Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | — | Active Not Recruiting | — | — | — |
NCT04115631CT.gov A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03863184CT.gov Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT04049513CT.gov ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) | — | Active Not Recruiting | — | — | — |
NCT04007029CT.gov Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03946878CT.gov Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03622788CT.gov Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT03710772CT.gov Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03674411CT.gov Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | — | Active Not Recruiting | — | — | — |
NCT03623373CT.gov Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03676504CT.gov Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | — | Recruiting | — | — | — |
NCT03314974CT.gov Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | — | Recruiting | — | — | — |
NCT03277729CT.gov A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT03246906CT.gov Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | — | Terminated | — | — | — |
NCT03035331CT.gov Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03153202CT.gov Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | — | Active Not Recruiting | — | — | — |
NCT02722668CT.gov UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | — | Completed | — | — | — |
NCT02972840CT.gov A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT02661035CT.gov Allo HSCT Using RIC for Hematological Diseases | — | Completed | — | — | — |
NCT02950220CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01962636CT.gov Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | — | Terminated | — | — | — |
NCT02914938CT.gov A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT02858258CT.gov ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT02735876CT.gov A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT02685670CT.gov Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | — | Unknown | — | — | — |
NCT02650999CT.gov Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | — | Completed | — | — | — |
NCT02858804CT.gov EDOCH Alternating With DHAP for New Diagnosed Younger MCL | — | Completed | — | — | — |
NCT02633137CT.gov Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02601313CT.gov Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | — | Completed | — | — | — |
NCT02356458CT.gov Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT02455297CT.gov Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | — | Terminated | — | — | — |
NCT02427620CT.gov Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT02153580CT.gov Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01163201CT.gov T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | — | Withdrawn | — | — | — |
NCT01865110CT.gov R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | — | Completed | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01812005CT.gov Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01695941CT.gov Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01597778CT.gov Double Cord Versus Haploidentical (BMT CTN 1101) | — | Completed | — | — | — |
NCT01439750CT.gov Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) | — | Unknown | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01527149CT.gov Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01389427CT.gov Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). | — | Completed | — | — | — |
NCT01397591CT.gov Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT01381692CT.gov Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | — | Completed | — | — | — |
NCT01504776CT.gov Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
NCT01322776CT.gov Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01111188CT.gov Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT01181271CT.gov Tandem Auto-Allo Transplant for Lymphoma | — | Completed | — | — | — |
NCT01184885CT.gov A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | — | Completed | — | — | — |
NCT01088048CT.gov Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
NCT01044745CT.gov Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | — | Terminated | — | — | — |
NCT00958256CT.gov Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | — | Completed | — | — | — |
NCT00490529CT.gov Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | — | Completed | — | — | — |
NCT00980395CT.gov Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | — | Completed | — | — | — |
NCT00942409CT.gov Study of Repeat Intranodal Injections of Ad-ISF35 | — | Terminated | — | — | — |
NCT01449344CT.gov Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | — | Unknown | — | — | — |
NCT00878254CT.gov Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00871546CT.gov SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | — | Terminated | — | — | — |
NCT00924326CT.gov CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | — | Completed | — | — | — |
NCT00807495CT.gov Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00789776CT.gov Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | — | Completed | — | — | — |
NCT00697346CT.gov Study of MLN8237 in Participants With Advanced Hematological Malignancies | — | Completed | — | — | — |
NCT00703664CT.gov Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT00644189CT.gov Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00722137CT.gov Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00791011CT.gov Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | — | Completed | — | — | — |
NCT00538187CT.gov Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT00594308CT.gov In-Vivo Activated T-Cell Depletion to Prevent GVHD | — | Terminated | — | — | — |
NCT00621452CT.gov Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00407303CT.gov Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
NCT00536601CT.gov High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | — | Completed | — | — | — |
NCT00348985CT.gov PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT00719888CT.gov Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | — | Completed | — | — | — |
NCT00103272CT.gov 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Terminated | — | — | — |
NCT00096005CT.gov Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Terminated | — | — | — |
NCT00209222CT.gov Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | — | Unknown | — | — | — |
NCT00082784CT.gov Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | — | Completed | — | — | — |
NCT00285389CT.gov Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | — | Completed | — | — | — |
NCT00005780CT.gov Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00581854CT.gov Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00022945CT.gov Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT04162756CT.gov Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Miltenyi Biomedicine GmbH | Approved | BB · 71 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →